South Africa

south-africa-small.jpgSouth Africa’s pharmaceutical market is one of the most attractive markets in Africa. Some of the main reasons for its rapid growth are the availability of cost-effective and skilled labor, high quality infrastructure, and the introduction of the South African Health Products Regulatory Authority (SAHPRA). The health care system aims to cover the entire population under the National Health Insurance (NHI) scheme, which it started implementing in a small population of 10 districts in 2012.

South Africa is home to drug major Aspen Pharma and privately owned Equity Pharma, however, most of the local drug manufacturers and distributors are in the hands of major international pharmaceutical firms.

In 2011, GBI Research valued the South African pharmaceutical market at $3.8 billion, and expects it to reach $7 billion in 2018 at a Compound Annual Growth Rate (CAGR) of 9.2%. South Africa’s healthcare sector is set to witness a number of new healthcare reform plans in the future, with the primary objective being to reduce the growing drug expenditure by increasing the use of generics.

According to GBI Research, generics accounted for over 60% of the volume of the pharmaceutical market in 2011. Government reforms have encouraged the manufacture and use of generic drugs as a tool to limit drug expenditure and provide low-cost effective public healthcare. The combination of government healthcare policies and numerous active generic manufacturing companies points to an increased generic market share in the forecast period.

Source: GBI Research

1 to 10 of 19 results

South Africa News

  • GSK joins with research councils in UK and South Africa to tackle non-communicable diseases in Africa

    GSK joins with research councils in UK and South Africa to tackle non-communicable diseases in Africa

    09-09-2014

    UK pharma giant GlaxoSmithKline today announced a £5 million ($8.2 million) collaboration with the UK and South African Medical Research Councils, to support much-needed research into non-communicable diseases in Africa, as part of GSK’s Africa NCD Open Lab initiative.

  • South Africa’s NAPM calls for elimination of VAT on medicines

    22-07-2014

    South African trade group the National Association of Pharmaceutical Manufacturers (NAPM) has proposed a zero Value Added Tax (VAT) rating of medicines in its submission to the Davis Tax Committee, tasked with assessing the country’s tax policy framework and its role in supporting the objectives of inclusive growth, employment, development and fiscal sustainability in South Africa.

  • Hemispherx links with SA biotech Bioclones on cancer vaccine

    Hemispherx links with SA biotech Bioclones on cancer vaccine

    14-07-2014

    USA-based Hemispherx Biopharma has entered a strategic alliance to develop multiple projects with Bioclones, a leading South African biotechnology company.

  • South Africa trade group intensifies efforts on generics access

    03-07-2014

    South Africa’s National Association of Pharmaceutical Manufacturer’s has appointed its new Executive Council, which has been tasked with strengthening the association’s strategic position within the pharmaceutical industry whilst representing the interests of its members and the broader public.

  • South Africa regulator gives MSF access to cheaper TB drug linezolid

    South Africa regulator gives MSF access to cheaper TB drug linezolid

    01-07-2014

    After a three-year long struggle, humanitarian aid agency Medecins Sans Frontieres has received approval from the South African Medicines Control Council to import a dramatically more affordable version of an antibiotic, linezolid, in order to expand access to the drug and provide better treatment options to patients with drug-resistant tuberculosis in Khayelitsha, Western Cape.

  • Adcock Ingram appoints CEO

    Adcock Ingram appoints CEO

    22-04-2014

    South African drugmaker Adcock Ingram has announced the appointment of Kevin Wakeford (pictured) as Chief Executive Officer, with immediate effect.

  • GlaxoSmithKline targets strategic investments in Africa

    02-04-2014

    Speaking at the 5th EU-Africa Business Forum in Brussels this week, Sir Andrew Witty, chief executive of UK drugs giant GlaxoSmithKline, set out the firm’s intent to partner with governments of African countries to help stimulate more research into chronic diseases, increase capacity by localizing medicines supply and strengthen health care infrastructure.

  • Pharma Summit: AIDS activists picket to demand South African reform

    Pharma Summit: AIDS activists picket to demand South African reform

    14-03-2014

    Delegates at The Economist’s Pharma Summit in London yesterday were greeted by AIDS activists picketing the entrance as they arrived.

  • Call for South African govt to ensure affordable medicines for all

    03-03-2014

    South Africa’s National Education, Health and Allied Workers' Union (NEHAWU) has reiterated its position, that the adoption of the National Policy on Intellectual Property is critical in reducing the price of medicines and in improving medication access for the vulnerable in the country’s society.

  • Adcock Ingram and CFR Pharma call off merger

    Adcock Ingram and CFR Pharma call off merger

    10-02-2014

    South Africa’s Adcock Ingram and Chile’s largest drugmaker CFR Pharmaceuticals have issued a joint statement terminating the increased $1.3 billion proposed acquisition of Adcock by the Chilean firm.

1 to 10 of 19 results

Back to top